Filing Details

Accession Number:
0001209191-19-017935
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-08 08:46:57
Reporting Period:
2019-03-07
Accepted Time:
2019-03-08 08:46:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1685071 Dova Pharmaceuticals Inc. DOVA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1494695 B Paul Manning 200 Garrett Street, Suite S
Charlottesville VA 22902
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-03-07 68,000 $7.48 12,950,954 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,783,226 Indirect By LLC
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.345 to $7.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
  2. Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 736,001 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.
  3. These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.